Comparative study of the use of antihypertensives and their relationship with sars-cov-2
DOI:
https://doi.org/10.56294/hl202296Keywords:
Angiotensin Converting Enzyme Inhibitors, Angiotensin, Receptor Blockers, Coronavirus Disease 2019, Cardiovascular DiseaseAbstract
This comparative study analyzed the published scientific evidence about the association between the reduction of severity or mortality due to COVID-19, and the efficiency of the use of Angiotensin Converting Enzyme Inhibitors (ACEIs) and angiotensin receptor blockers (BRAs) compared to other drugs antihypertensives non-ACEI/ARB in hypertensive patients.
The objective was to estimate the occurrence of the risk of morbidity, severity or mortality due severe acute respiratory failure in hypertensive patients and the efficacy of angiotensin-converting enzyme (ACE) and inhibitor drugs non-peptic Angio II receptor antagonists (ARBs II) in SARS-Cov-2.
The methodology used was the exhaustive bibliographic review of literary bases through the advanced search function of observational studies, clinical trials and meta-analyses that focus on the use of ACE Inhibitors/BRAs in SARS-Cov-2.
The ACEI and ARB results demonstrated better efficacy in terms of control of inflammatory processes and low risk of severity due to COVID-19 than CCBs. In addition, several studies affirm that there is a low risk of hospitalization, intubation and mortality from all cardiovascular causes during COVID-19 disease. Therefore, published scientific evidence suggests acceptable safety of the management of ACEIs
/ ARBs in SARS-Cov-2 and arterial hypertension in contrast to the few studies where ACEIs / ARBs increased the susceptibility of SARS-Cov-2, resulting in potential systemic damage. Conclusion: The medium-low quality of scientific evidence suggests an urgent need for a new systematic review that includes a greater number of randomized clinical trials, to corroborate the magnitude of the risk of morbidity, severity, and mortality from SARS-Cov-2.
References
Salazar M, Barochiner J, Espeche W, Ennis I. COVID-19 and its relationship with hypertension and cardiovascular disease. Hipertens Riesgo Vasc. 2020;37(4):176-80.
Torjesen I. Covid-19: Doctors should be alert for signs of myocardial injury, says NICE. BMJ. 2020;369:m1639.
Tignanelli CJ, Ingraham NE, Sparks MA, Reilkoff R, Bezdicek T, Benson B, et al. Antihypertensive drugs and risk of COVID-19? Lancet Respir Med. 2020.
;8(5):e30-1.
Ssentongo AE, Ssentongo P, Heilbrunn ES, Lekoubou A, Du P, Liao D, et al. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalized for COVID-19: systematic review and meta-analysis. Open Heart. 2020;7(2):e001353.
Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020;382(25):2431-40.
Kreutz R, Algharably EAE, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020;116(10):1688-99.
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-5.
Vuorio A, Watts GF, Kovanen PT. Familial hypercholesterolaemia and COVID-19: triggering of increased sustained cardiovascular risk. J Intern Med. 2020;288(4):456-8.
Vlachakis PK, Tentolouris A, Tousoulis D, Tentolouris N. Current data on the cardiovascular effects of the COVID-19. Hellenic J Cardiol. 2020;61(1):1-5.
Yang C, Jin Z. An acute respiratory infection runs into the most common noncommunicable epidemic-COVID-19 and cardiovascular diseases. JAMA Cardiol. 2020;5(7):723-5.
Yan T, Xiao R, Lin G. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword? FASEB J. 2020;34(5):6017-26.
Wynants L, Van Calster B, Bonten MMJ, Collins GS, Debray TPA, De Vos M, et al. Prediction models for diagnosis and prognosis of COVID-19 infection: systematic review and critical appraisal. BMJ. 2020;369:m1328.
Wood DA, Sathananthan J, Gin K, Mansour S, Ly HQ, Quraishi AU, et al. Precautions and procedures for coronary and structural cardiac interventions during the COVID-19 pandemic: Guidance from the Canadian Association of Interventional Cardiology. Can J Cardiol. 2020;36(6):780-3.
Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020;395(10228):e52.
Henry D. Antihypertensive drugs and COVID-19. Heart. 2021;107(1):85.
Villa E, Saccocci M, Messina A, Maffeo D, Piti A, Bianchetti F, et al. COVID-19 y enfermedad coronaria: uso selectivo y colaborativo de recursos durante crisis de salud pública. G Ital Cardiol (Rome). 2020;21(5):360-3.
Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med. 2020;382(25):2441-8.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38(5):781-2.
Duvignaud A, Lhomme E, Pistone T, Onaisi R, Sitta R, Journot V, et al. Home treatment of older people with symptomatic SARS-CoV-2 infection (COVID-19): a structured summary of a study protocol for a multi-arm multi-stage randomized trial. Trials. 2020;21(1):846.
Molina DI, Munoz TM, Guevara K. Inhibidores de la enzima convertidora de angiotensina y bloqueadores de los receptores de angiotensina II: ¿aumentan el riesgo de padecer COVID-19? Rev Colomb Cardiol. 2020;27(3):132-6.
Cohen JB, Hanff TC, Corrales-Medina V, William P, Renna N, Rosado-Santander NR, et al. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) trial protocol. J Clin Hypertens (Greenwich). 2020;22(10):1780-8.
Nouri-Vaskeh M, Kalami N, Zand R, Soroureddin Z, Varshochi M, Ansarin K, et al. Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomized clinical trial. Int J Clin Pract. 2021;75(6):e14124.
Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARS-CoV-2: Should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19):1801-3.
Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. J Card Fail. 2020;26(5):370.
Shimels T, Asrat Kassu R, Bogale G, Bekele M, Getnet M, Getachew A, et al. Magnitude and associated factors of poor medication adherence among diabetic and hypertensive patients visiting public health facilities in Ethiopia during the COVID-19 pandemic. PLoS One. 2021;16(4):e0249222.
Muchtaridi M, Fauzi M, Khairul Ikram NK, Mohd Gazzali A, Wahab HA. Natural flavonoids as potential angiotensin-converting enzyme 2 inhibitors for anti-SARS-CoV-2. Molecules. 2020;25(17):3980.
Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005;24(8):1634-43.
Hall JE, Guyton AC. Guyton y Hall. Tratado de fisiología médica. 13th ed. Barcelona: Elsevier; 2016. p. 227-43. ISBN: 978-84-9113-024-6.
Brunton LL, Chabner BA, Knollman BC. Las bases farmacológicas de la terapéutica. 12th ed. México DF: McGraw Hill; 2012. p. 721-88. ISBN: 978-0-07-162442-8.
Cabrera C. Sistema Renina Angiotensina Aldosterona. Ciudad Real: Hospital General Universitario de Ciudad Real (HGUCR); 2011 [cited 2025 Jan 17]. Available from: http://www.hgucr.es/wp-content/uploads/2011/12/eje_renina-angiotensina-aldosteromna.pdf.
Yokoyama Y, Aikawa T, Takagi H, Briasoulis A, Kuno T. Association of renin-angiotensin-aldosterone system inhibitors with mortality and testing positive of COVID-19: Meta-analysis. J Med Virol. 2021;93(4):2084-9.
Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653-9.
Trifiro G, Crisafulli S, Ando G, Racagni G, Drago F; Italian Society of P. Should patients receiving ACE inhibitors or angiotensin receptor blockers be switched to other antihypertensive drugs to prevent or improve prognosis of novel coronavirus disease 2019 (COVID-19)? Drug Saf. 2020;43(6):529-32.
Pranata R, Permana H, Huang I, Lim MA, Soetedjo NN, Supriyadi R, et al. The use of renin-angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14(5):983-90.
Hatami N, Ahi S, Sadeghinikoo A, Foroughian M, Javdani F, Kalani N, et al. Worldwide ACE (I/D) polymorphism may affect COVID-19 recovery rate: An ecological meta-regression. Endocrine. 2020;68(3):479-84.
Li L, Spranger L, Soll D, Beer F, Brachs M, Spranger J, et al. Metabolic impact of weight loss-induced reduction of adipose ACE-2: Potential implication in COVID-19 infections? Metabolism. 2020;113:154401.
Durán C, Marchand B, Jaramillo P, Herteleer J, Andrade A, Cevallos G, et al. Vademécum Farmacoterapeútico del Ecuador. 1st ed. Quito: Empresa Pública Yachay; 2015. p. 8.
Thiele H. Cardiovascular emergencies in the COVID-19 pandemic. Herz. 2020;45(4):345-50.
Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911-5.
Zuin M, Rigatelli G, Zuliani G, Rigatelli A, Mazza A, Roncon L. Arterial hypertension and risk of death in patients with COVID-19 infection: Systematic review and meta-analysis. J Infect. 2020;81(1):e84-e6.
Zekavat SM, Honigberg M, Pirruccello JP, et al. Elevated blood pressure increases pneumonia risk: Epidemiological association and Mendelian randomization in the UK Biobank. Med. 2020;2(2):137-48.
Zhu H, Rhee JW, Cheng P, Waliany S, Chang A, Witteles RM, et al. Cardiovascular complications in patients with COVID-19: Consequences of viral toxicities and host immune response. Curr Cardiol Rep. 2020;22(5):32.
Lukito A, et al. Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study. Int J Infect Dis. 2021;108:159-66.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.e8.
Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671-81.
Fosbøl EL, Butt JH, Østergaard L, Andersson C, Selmer C, Kragholm K, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020;324(2):168-77.
Lu IN, Kulkarni S, Fisk M, Kostapanos M, Banham-Hall E, Kadyan S, et al. muLTi-Arm Therapeutic study in pre-ICu patients admitted with COVID-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):690.
Abdullah M, Khan K, Javed M, Iqbal J, Waheed K, Akhtar MN, et al. A comparison of disease severity and outcomes in COVID-19 cases taking angiotensin-converting enzyme inhibitors/angiotensin receptor blockers versus other antihypertensive drugs. Cureus. 2021;13(1):e12757.
Barochiner J, Martínez R. Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis. J Clin Pharm Ther. 2020;45(6):1244-52.
Semenzato L, Botton J, Drouin J, Baricault B, Vabre C, Cuenot F, et al. Antihypertensive drugs and COVID-19 risk: A cohort study of 2 million hypertensive patients. Hypertension. 2021;77(3):833-42.
Wang Z, Zhang D, Wang S, Jin Y, Huan J, Wu Y, et al. A retrospective study from 2 centers in China on the effects of continued use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with hypertension and COVID-19. Med Sci Monit. 2020;26:e926651.
Zhang X, Yu J, Pan LY, Jiang HY. ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis. Pharmacol Res. 2020;158:104927.
Ren L, Yu S, Xu W, Overton JL, Chiamvimonvat N, Thai PN. Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis. J Cardiol. 2021;77(5):482-91.
Diaz JH. Hypothesis: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3):taaa044.
Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Baylor Univ Med Cent Proc. 2018;31(4):419-23.
Kerneis M, Ferrante A, Guedeney P, Vicaut E, Montalescot G. Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. Arch Cardiovasc Dis. 2020;113(11):779-88.
Ma Z, Wang MP, Liu L, Yu S, Wu TR, Zhao L, et al. Does taking an angiotensin inhibitor increase the risk for COVID-19? A systematic review and meta-analysis. Aging (Albany NY). 2021;13(8):10853-65.
Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.
Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, et al. Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: A systematic review and meta-analysis. JAMA Netw Open. 2021;4(3):e213594
Amat-Santos IJ, Santos-Martinez S, López-Otero D, Nombela-Franco L, Gutiérrez-Ibanes E, Del Valle R, et al. Ramipril in high-risk patients with COVID-19. J Am Coll Cardiol. 2020;76(3):268-76.
Xue Y, Sun S, Cai J, Zeng L, Wang S, Wang S, et al. Effects of ACEI and ARB on COVID-19 patients: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2020;21(4):1470320320981321.
Pirola CJ, Sookoian S. Estimation of renin-angiotensin-aldosterone-system (RAAS)-inhibitor effect on COVID-19 outcome: A meta-analysis. J Infect. 2020;81(2):276-81.
Baral R, White M, Vassiliou VS. Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: A systematic review and meta-analysis of 28,872 patients. Curr Atheroscler Rep. 2020;22(10):61.
Chu C, Zeng S, Hasan AA, Hocher CF, Krämer BK, Hocher B. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(6):2475-92.
Chan CK, Huang YS, Liao HW, Tsai IJ, Sun CY, Pan HC, et al. Renin-angiotensin-aldosterone system inhibitors and risks of severe acute respiratory syndrome coronavirus 2 infection: A systematic review and meta-analysis. Hypertension. 2020;76(5):1563-71.
Kow CS, Ming LC, Hasan SS. Renin-angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials. Hypertens Res. 2021;44(8):1042-5.
Biswas M, Kali MSK. Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: Meta-analysis. Sci Rep. 2021;11(1):5012.
Lopes RD, Macedo AVS, de Barros ESPGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: A randomized clinical trial. JAMA. 2021;325(3):254-64.
Flacco ME, Acuti Martellucci C, Bravi F, Parruti G, Cappadona R, Mascitelli A, et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: A meta-analysis. Heart. 2020;106(19):1519-24.
Kurdi A, Abutheraa N, Akil L, Godman B. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far? Pharmacol Res Perspect. 2020;8(6):e00666.
Grover A, Oberoi M. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Eur Heart J Cardiovasc Pharmacother. 2021;7(2):148-57.
Patoulias D, Katsimardou A, Stavropoulos K, Imprialos K, Kalogirou MS, Doumas M. Renin-angiotensin system inhibitors and COVID-19: A systematic review and meta-analysis. Evidence for significant geographical disparities. Curr Hypertens Rep. 2020;22(11):90.
Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: A prospective, randomized, open-label trial. Lancet Respir Med. 2021;9(3):275-84.
Kerneis M, Ferrante A, Guedeney P, Vicaut E, Montalescot G. Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. Arch Cardiovasc Dis. 2020;113(12):797-810.
Verdecchia P, Reboldi G, Cavallini C, Mazzotta G, Angeli F. ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus. G Ital Cardiol (Rome). 2020;21(5):321-7.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8.
Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020;92(7):726-30.
Usman MS, Siddiqi TJ, Khan MS, Ahmed A, Ali SS, Michos ED, et al. A meta-analysis of the relationship between renin-angiotensin-aldosterone system inhibitors and COVID-19. Am J Cardiol. 2020;130:159-61.
Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): A prospective, parallel group, randomized, controlled, open-label trial. Lancet Respir Med. 2021;9(8):863-72.
Qiu R, Li J, Xiao Y, Gao Z, Weng Y, Zhang Q, et al. The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100(16):e25532.
Xu J, Teng Y, Shang L, Gu X, Fan G, Chen Y, et al. The effect of prior angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment on coronavirus disease 2019 (COVID-19) susceptibility and outcome: A systematic review and meta-analysis. Clin Infect Dis. 2021;72(11):e901-13.
Zhang G, Wu Y, Xu R, Du X. Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: A meta-analysis. J Med Virol. 2021;93(4):2287-300.
Koshy AN, Murphy AC, Farouque O, Ramchand J, Burrell LM, Yudi MB. Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: A systematic review and meta-analysis. Intern Med J. 2020;50(12):1468-74.
Sattar Y, Mukuntharaj P, Zghouzi M, Suleiman AM, Attique H, Ullah W, et al. Safety and efficacy of renin-angiotensin-aldosterone system inhibitors in COVID-19 population. High Blood Press Cardiovasc Prev. 2021;28(4):405-16.
Greco A, Buccheri S, D'Arrigo P, Calderone D, Agnello F, Monte M, et al. Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: A systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2020;6(5):335-7.
Lee HW, Yoon CH, Jang EJ, Lee CH. Renin-angiotensin system blocker and outcomes of COVID-19: A systematic review and meta-analysis. Thorax. 2021;76(5):479-86.
Bezabih YM, Bezabih A, Alamneh E, Peterson GM, Bezabhe W. Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes. BMC Infect Dis. 2021;21(1):527.
Hasan SS, Kow CS, Hadi MA, Zaidi STR, Merchant HA. Mortality and disease severity among COVID-19 patients receiving renin-angiotensin system inhibitors: A systematic review and meta-analysis. Am J Cardiovasc Drugs. 2020;20(6):571-90.
Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11):e138999.
Zuckier LS, Moadel RM, Haramati LB, Freeman L. Diagnostic evaluation of pulmonary embolism during the COVID-19 pandemic. J Nucl Med. 2020;61(5):630-5.
Lee SA, Park R, Yang JH, Min IK, Park JT, Han SH, et al. Increased risk of acute kidney injury in coronavirus disease patients with renin-angiotensin-aldosterone-system blockade use: A systematic review and meta-analysis. Sci Rep. 2021;11(1):13588.
Kaur U, Acharya K, Mondal R, Singh A, Saso L, Chakrabarti S, et al. Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2. Eur J Pharmacol. 2020;887:173545.
Roldán J. Farmacovigilancia: datos sobre el estado actual de esta disciplina en Chile. Rev Med Clin Las Condes. 2016;27(5):585-93.
Hernández M, Tribiño G, Bustamante C. Caracterización de las potenciales interacciones farmacológicas en pacientes de una unidad de cuidados intensivos en un hospital de tercer nivel de Bogotá. Biomédica. 2018;38(3):407-16.
Bai L, Dai H, Xu Q, Junaid M, Peng S, Zhu X, et al. Prediction of effective drug combinations by an improved naïve Bayesian algorithm. Int J Mol Sci. 2018;19(2):467.
Cui Z, Gao Y, Liu J, Wang J, Shang J, Dai L. La predicción computacional de interacciones fármaco-enfermedad utilizando el método L2,1-CMF de red dual. BMC Bioinformatics. 2019;20(1):5.
Zhou YH, Qin YY, Lu YQ, Sun F, Yang S, Harypursat V, et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: Protocol of a randomized controlled trial. Chin Med J (Engl). 2020;133(9):1080-6.
Ye XT, Luo YL, Xia SC, Sun QF, Ding JG, Zhou Y, et al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020;24(6):3390-6.
Published
Versions
- 2025-02-23 (2)
- 2022-12-31 (1)
Issue
Section
License
Copyright (c) 2022 Franklin Francisco Castro Mindiola, Pilar Asunción Soledispa Cañarte (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
